Inhibikase Therapeutics, Inc. (IKT)
1.63
-0.04
(-2.40%)
USD |
NASDAQ |
Jan 20, 10:31
Inhibikase Therapeutics EPS Diluted (Quarterly): -0.1325 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| CEL-SCI Corp. | -0.7611 |
| AIM ImmunoTech, Inc. | -1.567 |
| IGC Pharma, Inc. | -0.0201 |
| NovaBay Pharmaceuticals, Inc. | -0.22 |
| Protalix Biotherapeutics, Inc. | 0.0291 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.93M |
| Total Expenses (Quarterly) | 11.93M |
| Enterprise Value | 125.19M |
| Earnings Yield | -34.99% |
| Normalized Earnings Yield | -35.95 |